EPIDEMIOLOGY AND BURDEN OF HOSPITALISATIONS FOR VIRAL LOWER RESPIRATORY TRACT DISEASES: A FRENCH NATIONWIDE RETROSPECTIVE COHORT STUDY 2022-2024 (VINCA STUDY)
Author(s)
Laurent Guilleminault, MD, PhD1, Paul Loubet, MD, PhD2, Caroline FABRY-VENDRAND, PharmD3, Ophélie Rouxel, PhD3, Delphine Leynaud, PhD3, Aurélien Carlicchi, PharmD, MSc4, Isabelle Bureau, MSc4, Camille Nevoret, PhD4, Stephane Bouee, MD, MSc4, Nicolas de Prost, MD, PhD5.
1Pôle des voies respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France, 2Service des maladies infectieuses, CHU de Nimes, Nimes, France, 3AstraZeneca, Courbevoie, France, 4RWE, CEMKA, Bourg-la-Reine, France, 5GHU Henri Mondor, Créteil, France.
1Pôle des voies respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France, 2Service des maladies infectieuses, CHU de Nimes, Nimes, France, 3AstraZeneca, Courbevoie, France, 4RWE, CEMKA, Bourg-la-Reine, France, 5GHU Henri Mondor, Créteil, France.
OBJECTIVES: Several million viral lower respiratory tract diseases (vLRTD) occur each year, leading to hospitalisations, predominantly among vulnerable individuals. This study aims to estimate the burden of hospitalisations for vLRTD in France.
METHODS: The database of the Programme for the Medicalisation of Information Systems (PMSI), covering all hospital admissions in France, was used. Patients admitted to acute care (MCO) with at least one ICD-10 code related to acute respiratory infection were selected over two epidemic years, from 1 September 2022 to 31 August 2024. An episode of vLRTD was defined as a hospitalisation with a principal diagnosis of vLRTD or an associated diagnosis of vLRTD associated with respiratory severity factors or a transfer to an intensive care unit (ICU).
RESULTS: During the two epidemic years studied, 911,818 hospitalisations for respiratory tract infections were identified, of which 38% (n=345,050) were of viral origin (study population): mean age 56.0 years, 53% male. The breakdown of main viral aetiologies was: COVID-19 (208,687;62%), respiratory syncytial virus (60,105;18%) and influenza virus (40,888;12%). 78% of patients ≥18years had at least one relevant comorbidity: cardiovascular (68%), respiratory (27%, comprising 17% with COPD/Emphysema) and 26% with immunosuppression. An asthma exacerbation was reported for 5,072 hospitalisations (1.5%), and COPD exacerbation for 10,179 (3.0%). Admission to an intensive care unit/continuous monitoring was observed in 31% of hospitalisations. A readmission within 90 days occurred in 101,113 subjects (31.8%), of whom 9,339 (2.9%) were readmitted for bacterial/viral respiratory tract infection. 33,375 patients (9.8%) died during the initial hospitalisation (24,803;74.3%) or during re-hospitalisation within 90 days (8,572;25.7%). The mean index hospitalization cost was €6,785, with additional readmission costs of €6,453 within 30 days and €8,461 within 90 days.
CONCLUSIONS: The burden of hospitalisations associated with vLRTD is considerable, with notably high rates of death and rehospitalisation within 90 days.
METHODS: The database of the Programme for the Medicalisation of Information Systems (PMSI), covering all hospital admissions in France, was used. Patients admitted to acute care (MCO) with at least one ICD-10 code related to acute respiratory infection were selected over two epidemic years, from 1 September 2022 to 31 August 2024. An episode of vLRTD was defined as a hospitalisation with a principal diagnosis of vLRTD or an associated diagnosis of vLRTD associated with respiratory severity factors or a transfer to an intensive care unit (ICU).
RESULTS: During the two epidemic years studied, 911,818 hospitalisations for respiratory tract infections were identified, of which 38% (n=345,050) were of viral origin (study population): mean age 56.0 years, 53% male. The breakdown of main viral aetiologies was: COVID-19 (208,687;62%), respiratory syncytial virus (60,105;18%) and influenza virus (40,888;12%). 78% of patients ≥18years had at least one relevant comorbidity: cardiovascular (68%), respiratory (27%, comprising 17% with COPD/Emphysema) and 26% with immunosuppression. An asthma exacerbation was reported for 5,072 hospitalisations (1.5%), and COPD exacerbation for 10,179 (3.0%). Admission to an intensive care unit/continuous monitoring was observed in 31% of hospitalisations. A readmission within 90 days occurred in 101,113 subjects (31.8%), of whom 9,339 (2.9%) were readmitted for bacterial/viral respiratory tract infection. 33,375 patients (9.8%) died during the initial hospitalisation (24,803;74.3%) or during re-hospitalisation within 90 days (8,572;25.7%). The mean index hospitalization cost was €6,785, with additional readmission costs of €6,453 within 30 days and €8,461 within 90 days.
CONCLUSIONS: The burden of hospitalisations associated with vLRTD is considerable, with notably high rates of death and rehospitalisation within 90 days.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH121
Topic
Epidemiology & Public Health, Real World Data & Information Systems, Study Approaches
Disease
Infectious Disease (non-vaccine), Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)